Clinical trials: Hepatitis C
Chronic Hepatitis C
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin…
- Trial name
- NCT02807402
- Volunteers
- 522 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus…
- Trial name
- NCT02722837
- Testing
- SOF/VEL
- Where
- 15 sites in Russia, Sweden
- Volunteers
- 119 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment…
- Trial name
- NCT01330316
- Testing
- BI 201335, PegIFN/RBV
- Where
- 87 sites in United States, Austria and 13 more
- Volunteers
- 119 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.
- Trial name
- CERTAIN-2 (NCT02723084)
- Testing
- ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV)
- Volunteers
- 136 people
- Sponsor
- AbbVie
Chronic Hepatitis C Infection
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin…
- Trial name
- ZIRCON (NCT02486406)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AbbVie
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
This was a Phase 3, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) for an 8 or 12-week treatment duration in adults in Brazil with chronic hepatitis C virus (HCV)…
- Trial name
- NCT03219216
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 14 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
The primary objectives of this study are to evaluate the safety, efficacy and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) in adults with chronic HCV infection who are on dialysis for ESRD.
- Trial name
- ESRD (NCT03036839)
- Testing
- LDV/SOF
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 95 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C…
- Trial name
- NCT01853254
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
PegIntron Injection Surveillance Plan (Study P04123)
Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with chronic hepatitis C are generally treated.
- Trial name
- NCT00723931
- Testing
- Peginterferon alfa-2b (SCH 54031)
- Volunteers
- 1,267 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C (HCV)
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that…
- Trial name
- NCT00807001
- Testing
- IDX184
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study of Oral Treatments for Hepatitis C
Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions.
- Trial name
- PRIORITIZE (NCT02786537)
- Testing
- SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir)
- Where
- 38 sites in United States
- Volunteers
- 1,275 people
- Sponsor
- University of Florida
Hepatitis C, Chronic
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients…
- Trial name
- NCT01675427
- Testing
- Interleukin 28B testing
- Where
- 210 sites in United States, Argentina and 29 more
- Volunteers
- 4,766 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the…
- Trial name
- CONCISE (NCT01459913)
- Testing
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 83 sites in United States, Austria and 4 more
- Volunteers
- 239 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HCV Infection
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
- Trial name
- NCT00726882
- Testing
- Blood sample collection only, ABT-333
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections, Sexually Transmitted Diseases, Bacterial
Mobile Enhanced Prevention Support for People Leaving Jail
This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail.
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
- Trial name
- MEPS (NCT04036396)
- Testing
- Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
- Where
- 3 sites in United States
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatitis C, Chronic
Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)
This is a single-arm, multicenter study of boceprevir (BOC) in combination with peginterferon plus ribavirin (PEG/RBV) in adult chronic hepatitis C (CHC) genotype 1 participants who completed their per-protocol defined treatment…
- Trial name
- PROVIDE (NCT00910624)
- Testing
- Boceprevir, Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 168 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are…
- Trial name
- GEODE II (NCT02609659)
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin
- Volunteers
- 105 people
- Sponsor
- AbbVie
Hepatitis C
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
- Trial name
- NCT01389323
- Testing
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 448 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic…
- Trial name
- NCT02822794
- Testing
- SOF/VEL, RBV
- Where
- 18 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)
The purpose of this study is to assess anti-viral activity (inhibition of viral growth) of TMC435350 in genotype 2,3,4,5 and 6 hepatitis C virus infected participants who have never received treatment for their hepatitis C…
- Trial name
- NCT00812331
- Testing
- TMC435
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland